Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.

Abstract excerpt

Gastrointestinal stromal tumor (GIST) is the most common type of sarcoma of the gastrointestinal tract, with approximately 5000 new cases annually in the USA. Approximately 80% of GIST cases are driven by activating mutations in KIT in exon 9 or 11. Resistance to present therapies like imatinib often arises from secondary KIT mutations, especially V654A (exon 13), which is the most frequent resistance mutation....

Topics

Join the communities discussing this publication.

• Drug Design
• Gastrointestinal Stromal Tumors
• Imatinib Mesylate
• Naphthyridines
• Proto-Oncogene Proteins c-kit